HC Wainwright Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $22.00

Viridian Therapeutics (NASDAQ:VRDN) had its price objective reduced by HC Wainwright from $34.00 to $22.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Viridian Therapeutics’ Q1 2026 earnings at ($1.16) EPS, Q2 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.17) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($3.51) EPS, FY2028 earnings at ($2.84) EPS, FY2029 earnings at ($1.33) EPS and FY2030 earnings at $0.71 EPS.

Other equities analysts have also recently issued reports about the stock. Truist Financial cut their target price on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. Needham & Company LLC dropped their price objective on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday. Evercore reaffirmed an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Finally, Royal Bank Of Canada lowered their price target on Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $39.21.

Viridian Therapeutics Stock Down 1.6%

Shares of NASDAQ VRDN opened at $18.84 on Tuesday. The business has a 50-day moving average price of $28.63 and a 200 day moving average price of $27.77. The stock has a market cap of $1.93 billion, a PE ratio of -5.73 and a beta of 1.16. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $15.75 million. Equities research analysts forecast that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Several institutional investors have recently bought and sold shares of VRDN. Avoro Capital Advisors LLC acquired a new stake in Viridian Therapeutics in the fourth quarter valued at $46,680,000. Seven Fleet Capital Management LP acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth $456,000. Virtu Financial LLC acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth $531,000. Invesco Ltd. increased its holdings in shares of Viridian Therapeutics by 127.1% in the 4th quarter. Invesco Ltd. now owns 183,468 shares of the company’s stock valued at $5,710,000 after purchasing an additional 102,676 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Viridian Therapeutics in the 4th quarter valued at about $1,464,000.

Trending Headlines about Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Topline REVEAL-1 Phase III results reported clinical activity for elegrobart — supports the drug’s efficacy and preserves an approval/commercial pathway, which is a material long-term positive for VRDN. Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
• Positive Sentiment: Some analysts remain constructive on longer-term upside: HC Wainwright maintains a Buy and has modeled recovery into FY2029–2030 (including a FY2030 EPS projection), reflecting belief in commercial potential beyond near-term noise. (Market commentary / analyst note summaries)
• Neutral Sentiment: Short-term trading has been volatile — the stock saw large swings on volume as the market digested nuanced efficacy/market-position takeaways; that raises short-term uncertainty but also increases liquidity for active traders. Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
• Negative Sentiment: Market reaction included a sharp pre-market drop (reported ~41% at one point) as investors judged the results insufficiently dominant versus competitors and priced in execution/market-share risk. VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal?
• Negative Sentiment: Several firms lowered expectations/targets after the readout: Goldman cut its price target, Wells Fargo trimmed its target to $20, and other notes signaled more cautious near-term forecasts — increasing near-term downside risk from analyst-driven flows. The Goldman Sachs Group Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 Wells Fargo & Company Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $20.00 Wedbush Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
• Negative Sentiment: Critical takes emphasize that REVEAL-1 returned clinically meaningful but not clearly market-dominant data, which may limit peak sales vs. competitors and lengthen the commercialization ramp — a negative for near- to medium-term valuation. Viridian’s REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.